Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

TUSTIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients. The trial's planned total of 46 patients has been enrolled and patients are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label study is to assess the overall tumor response to the regimen of bavituximab in combination with carboplatin/paclitaxel. Separately, the company announced issuance of a new U.S. patent with claims covering the use of bavituximab in combination with a broad range of cancer therapeutic agents. Peregrine is currently conducting three separate Phase II studies testing bavituximab in combination with docetaxel or carboplatin and paclitaxel in advanced breast and lung cancer patients. These combination therapies, which have shown promising initial results, are all covered under the claims in the newly issued patent.

"It is fitting that this new U.S. patent protecting the use of bavituximab in combination with a variety of anti-cancer therapeutics has issued as enrollment in each of our three Phase II trials of bavituximab in combination with chemotherapy is either completed or nearing completion," said Steven W. King, president and CEO of Peregrine. "There is considerable evidence that bavituximab and other anti-PS antibodies act synergistically with standard cancer treatments, and the additional protection provided by this new patent further strengthens our intellectual property leadership in the field of PS-targeting therapeutics."

U.S. Patent #7,572,448 covers the therapeutic use of bavituximab and rela
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Hahnemann among the Best in the Nation ... Hospital proudly announces it has been granted Magnet(R) ... Magnet Recognition Program(R). Magnet(R) is one of the ... center can achieve, and places Hahnemann among the ... have achieved this prestigious distinction. ,, At 9:00 ...
(Date:12/16/2009)... INDIANAPOLIS, Dec. 16 /PRNewswire/ -- ... Indiana,s life sciences industry and an active venture ... Company, Indiana State Teachers Retirement Fund, Indiana University, ... M. Fairbanks Foundation, and Credit Suisse today announced ... million venture capital fund of funds. ,, Organized ...
(Date:12/16/2009)... Dec. 16 Sequenom, Inc. (Nasdaq: ... Kenneth Buechler and Mr. David Pendarvis to its ... http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) ,, Kenneth F. Buechler, Ph.D., was ... Incorporated. From 1988 to 1994, Dr. Buechler was ... Dr. Buechler was a senior research scientist for ...
(Date:12/16/2009)... HAMBURG, Germany, December 16 Eppendorf ... Verigene(R) and Verigene(R) SP systems for,infringement of ... titled "Method for the,identification and/or the quantification ... any and all imports of the respective ... Customs authorities are required to confiscate any,violating ...
Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2
... , , , Includes QIAGEN EZ Competent Cells for added , convenience, , , , ... Component , Included , Concentration , ... , , , ... , 50 ng/l, , ...
... , , For robust amplification in all applications, , , , , , , ... Included , Concentration , , ... , , , , ... 5 units/l , , , ...
... , , , , ... from QIAGEN allows , efficient gene silencing in ... mRNA. This effect, termed RNA interference (RNAi), enables targeted , ... , siRNA oligonucleotide synthesis service that includes a ...
Other Biology Technology:Custom and library siRNA for efficient gene silencing 2Custom and library siRNA for efficient gene silencing 3Custom and library siRNA for efficient gene silencing 4Custom and library siRNA for efficient gene silencing 5
(Date:12/16/2009)... YORK, Dec. 1 iQor, a global provider ... the 2009 InfoWorld 100 Awards Top 100 ... TeQ21. This was the first submission for iQor. ,, ... list of companies," said Vikas Kapoor, president and CEO ... do business, allowing us to work faster, smarter and ...
(Date:12/16/2009)... Dec. 3 BIO-key International, Inc. ... wireless public safety and finger-based biometric identification ... shareholders at a Special Shareholder Meeting held ... Law Enforcement Division to Interact911 Mobile Systems ... cast in favor and 1.2% were opposed. ...
(Date:12/16/2009)... Dec. 9 CSC (NYSE: ... American Association for Laboratory Accreditation awarded the ... 17025:2005 accreditation to the company,s Test Lab, ... Labs located in Fairmont, W.Va. The Test ... in the world to achieve this accomplishment. ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Immucor to Announce Fiscal First Quarter Financial Results on Thursday October 1 2009 57569 1Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 1Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 2Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 3Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 5Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 6Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 7Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7
... of particulate air pollution may increase the risk of ... exposure standards could be insufficient to protect the public. ... exposed to ambient air pollution at the levels observed ... potentially large public health impact," said Lynda Lisabeth, lead ...
... nutrient that dictates productivity (and thus carbon consumption) in ... nitrogen enters the forest through cyanobacteria living on the ... on the forest floor. These bacteria convert nitrogen ... used by other living organisms, a process referred to ...
... demand for and price of oil and other sources ... for abundant, cost-effective alternative sources of energy. One ... is the focus of a new book by ASM ... fuels and the devastating effects of ever-increasing greenhouse gases, ...
Other Biology News:Even low levels of air pollution may pose stroke risk 2Forest canopies help determine natural fertilization rates 2New text highlights role of microorganisms in alternative energy development 2
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
... Large T antigen initiates replication ... replication in the presence of ... product can be used in ... Replication Kit cat. no. 8050. ...
Request Info...
Anti-hamster Ig HRP detection kit...
Biology Products: